血管紧张素转换酶基因型与重庆地区人群原发性高血压药物治疗的关系

目的 探讨重庆地区人群血管紧张素转换酶基因（ＡＣＥ）插入／缺失（Ｉ／Ｄ）多态性与原发性高血压及药物治疗的关系。方法 用多聚酶链反应直接扩增ＡＣＥ基因第１６内含子，对１１４名正常人和７５例原发性高血压患者进行了分析，同时对４９例原发性高血压患者用血管紧张素转换酶抑制剂（ＡＣＥＩ，依拉普利）和钙通道阻滞剂（ＣＣＢ，菲洛地平）进行自身交叉治疗，并比较降压效果。结果 原发性高血压患者ＡＣＥ基因的ＤＤ型频率

The relationship of angiotensin-converting enzyme gene to essential hypertension and drug treatment in Chongqing

Objective To measure and discuss the association of the angiotensin converting enzyme (ACE) gene insertion/deletion(I/D) polymorphism with essential hypertension and drug treatment in Chongqing. Methods Polymerase chain reaction(PCR) method was used to amplify the sixteenth intron of the ACE gene for the analysis of 114 healthy controls and 75 patients with essential hypertension. At the same time, 49 patients with essential hypertension were randomly divided into two groups for a placebo controlled crossover comparison of ACEI versus CCB. Results The frequency of homozygous alleles DD and the frequency of deletion alleles were significantly higher in the essential hypertension group than in the healthy controls( P <0.005). The blood pressure decreased more in the DD genotype subjects when treated with the ACEI but decreased less when treated with the CCB (15.91 vs 12.43, P >0.1). The blood pressure decreased more in the II genotype subjects when treated with the CCB but decreased less when treated with the ACEI (16.55 vs 9.6, P <0.05). Conclusion The results indicate that a deletion (DD) polymorphism of the ACE gene is associated with essential hypertension in Chongqing. Detection of the ACE genotype in clinics is helpful to the selection of antihypertensive drugs.